These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 10830740)

  • 1. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations.
    Tomita N; Kodama F; Sakai R; Koharasawa H; Hattori M; Taguchi J; Fujita H; Tanabe J; Fujisawa S; Fukawa H; Harano H; Kanamori H; Miyashita H; Matsuzaki M; Ogawa K; Motomura S; Maruta A; Ishigatsubo Y
    Leuk Lymphoma; 2000 Jul; 38(3-4):335-43. PubMed ID: 10830740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: the EBMT experience. Lymphoma Working Party of the European Group for Bone Marrow Transplantation.
    Sweetenham JW; Proctor SJ; Blaise D; De Laurenzi A; Pearce R; Taghipour G; Goldstone AH; Laurenzi A [corrected to De Laurenzi A]
    Ann Oncol; 1994; 5 Suppl 2():155-9. PubMed ID: 7515646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Boehme V; Zeynalova S; Kloess M; Loeffler M; Kaiser U; Pfreundschuh M; Schmitz N
    Ann Oncol; 2007 Jan; 18(1):149-157. PubMed ID: 17018708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Central nervous system relapse in diffuse large B cell lymphoma: Risk factors].
    Sancho JM; Ribera JM;
    Med Clin (Barc); 2016 Jan; 146(2):74-80. PubMed ID: 25817451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
    Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of serum beta 2 microglobulin as an indicator of early relapse in diffuse large cell lymphoma.
    Avilés A; Narváez BR; Díaz-Maqueo JC; Guzmán R; Talavera A; García EL
    Leuk Lymphoma; 1993 Mar; 9(4-5):377-80. PubMed ID: 7688627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CNS involvement in children with newly diagnosed non-Hodgkin's lymphoma.
    Sandlund JT; Murphy SB; Santana VM; Behm F; Jones D; Berard CW; Furman WL; Ribeiro R; Crist WM; Greenwald C; Chen G; Walter A; Pui CH
    J Clin Oncol; 2000 Aug; 18(16):3018-24. PubMed ID: 10944136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of poor prognosis non-Hodgkin's lymphoma with intensive, inpatient combination chemotherapy of brief duration: long-term followup.
    Waits TM; Greco FA; Greer JP; Hainsworth JD
    Leuk Lymphoma; 1993 Aug; 10(6):453-9. PubMed ID: 7691308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma.
    Dhaliwal HS; Rohatiner AZ; Gregory W; Richards MA; Johnson PW; Whelan JS; Gallagher CJ; Matthews J; Ganesan TS; Barnett MJ
    Br J Cancer; 1993 Oct; 68(4):767-74. PubMed ID: 8398705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte.
    Morel P; Dupriez B; Herbrecht R; Bastion Y; Tilly H; Delannoy A; Haioun C; Nouvel C; Bouabdallah K; Baumelou E
    Br J Cancer; 1994 Jul; 70(1):154-9. PubMed ID: 7517172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [M-BACOD in advanced case of non-Hodgkin's lymphoma].
    Itami J; Ogata H; Shimizu K; Nemoto K; Yasuda S; Yoshida H; Mikata A; Arimizu N
    Gan No Rinsho; 1990 Mar; 36(4):499-504. PubMed ID: 1690824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
    Reiter A; Schrappe M; Tiemann M; Ludwig WD; Yakisan E; Zimmermann M; Mann G; Chott A; Ebell W; Klingebiel T; Graf N; Kremens B; Müller-Weihrich S; Plüss HJ; Zintl F; Henze G; Riehm H
    Blood; 1999 Nov; 94(10):3294-306. PubMed ID: 10552938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
    Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC
    J Clin Oncol; 1994 Oct; 12(10):2153-9. PubMed ID: 7523607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
    Waits TM; Greco FA; Greer JP; Johnson DH; Wolff SN; Stein RS; McMaster ML; Hainsworth JD
    J Clin Oncol; 1993 May; 11(5):943-9. PubMed ID: 7683712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group.
    Oguchi M; Ikeda H; Isobe K; Hirota S; Hasegawa M; Nakamura K; Sasai K; Hayabuchi N
    Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):161-8. PubMed ID: 10924986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
    Ravandi F; Cortes J; Estrov Z; Thomas D; Giles FJ; Huh YO; Pierce S; O'Brien S; Faderl S; Kantarjian HM
    Leuk Res; 2002 Jul; 26(7):643-9. PubMed ID: 12008081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
    Alvarnas JC; Negrin RS; Horning SJ; Hu WW; Long GD; Schriber JR; Stockerl-Goldstein K; Tierney K; Wong R; Blume KG; Chao NJ
    Biol Blood Marrow Transplant; 2000; 6(3A):352-8. PubMed ID: 10905773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.